Nabriva Therapeutics has acquired Zavante Therapeutics, a biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patient.    The deal includes upfront consideration of approximately 8.2 million of Nabriva Therapeutics’ ordinary shares to Zavante Therapeutics’ former stockholders upon completion of the acquisition. In addition, Zavante Therapeutics’ former stockholders are eligible to receive up to $97.5 million upon the achievement of spec...